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Introduction: The survival effectiveness of neoadjuvant chemo-
therapy in non-small cell lung cancer (NSCLC) is still unclear based
on the study of most up-to-date literatures. This article contributes to
this problem by conducting an updated meta-analysis.
Methods: Based on Burdett et al’s (J Thorac Oncol 2006;1:611–
621) systematic review, this meta-analysis was conducted. Articles
were searched electrically. The possible survival benefit of neoad-
juvant chemotherapy was assessed by hazard ratio (HR) in terms of
overall survival. A subgroup meta-analysis with only stage III
NSCLC was also conducted. The software of Review Manager was
used for data management.
Results: Thirteen randomized control trials, 6 of which were new
ones, were included into this meta-analysis. The overall survival of
NSCLC patients in neoadjuvant chemotherapy arm were improved
significantly, comparing with those in surgery-alone arm (combined
HR  0.84; 95% confidence interval, 0.77–0.92; p  0.0001).
When only patients with stage III NSCLC were considered, the
result was similar (combined HR  0.84; 95% confidence interval,
0.75–0.95; p  0.005).
Conclusion: Neoadjuvant chemotherapy, as an addition of surgery,
would significantly improve the overall survival of operable NSCLC
patients, including patients with stage III NSCLC.
Key Words: Non-small cell lung cancer, Neoadjuvant chemother-
apy, Surgery, Survival, Randomized control trial, Meta-analysis.
(J Thorac Oncol. 2010;5: 510–516)
In 2006, Burdett et al.1 published a systematic review toclarify the effectiveness of neoadjuvant chemotherapy in
patients with non-small cell lung cancer (NSCLC). In their
review, they conducted a meta-analysis (quantitative assess-
ment) and discovered a survival benefit of neoadjuvant che-
motherapy in operable NSCLC patients. Their results
strengthened neoadjuvant chemotherapy as a strategic treat-
ment choice for operable NSCLC patients for the sake of
long-time survival. Nevertheless, the data supporting their
conclusion seemed a little weak in respect that there were
only seven eligible trials included in that analysis and that
most of those included trials were small-scale ones.
In the following years, researchers from different parts
of the world published several articles with different conclu-
sions on neoadjuvant chemotherapy in NSCLC. For example,
in 2007, Gilligan et al.2 reported a multicenter randomized
trial (named as MRC LU22) with results indicating that
neoadjuvant chemotherapy might not benefit NSCLC patients
in terms of long-time survival. MRC LU22 was a large-scale
randomized control trial (RCT) performed by researchers of
several different European countries, with totally 519 eligible
NSCLC patients enrolled. Follow at heel, in 2008, in the
Meeting of American Society of Clinical Oncology (ASCO),
Scagliotti et al.3 reported another large-scale RCT with totally
270 eligible patients, and their results supported neoadjuvant
chemotherapy as an beneficial addition of surgery in NSCLC.
In addition, researchers from China had also reported their
results on this subject in recent years, and different conclu-
sions were reached.
Because the conclusions of those newly reported trials
were inconsistent, it seemed still confusing whether neoad-
juvant chemotherapy would benefit NSCLC patients in view
of long-time survival. Therefore, we believed that there was
a need to conduct an updated meta-analysis of neoadjuvant
chemotherapy to clarify it, and here, based on Burdett et al.’s
meta-analysis, an updated meta-analysis was performed.
METHODS
Trials Search and Criteria of Eligibility
All those seven eligible trials4–12 analyzed in Burdett et al.’s
meta-analysis were taken into this updated meta-analysis. In
addition, we also performed a search work for the following:
(1) eligible trials published/reported in English or Chinese,
which were not included in Burdett et al.’s meta-analysis; and
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(2) articles with updated data for trials that had been ana-
lyzed. Trial search was performed in April 2009, using the
keywords of “lung cancer  neoadjuvant/induction/preopera-
tive chemotherapy” on PubMed (online, 2005–2009),
Chinese Biomedical Disc (1978–2009), and ASCO Annual
Meeting abstracts (2006–2008). References in reviews con-
cerning neoadjuvant chemotherapy for NSCLC were also
read to search for eligible trials.13–17
Criteria of eligibility for every eligible trial included (1)
to investigate the survival effects of neoadjuvant chemother-
apy, as an addition of surgery, in NSCLC patients; (2) to be
RCT or phase III randomized study, published as full-length
article or abstract; (3) to be published/reported in English or
Chinese publicly.
Data Extraction and Statistical Methods
Before data extraction, all the authors had read every
eligible article completely, and a quality assessment of every
article was performed according to the Consolidated Stan-
dards of Reporting Trials (CONSORT) statement.18
Hazard ratio (HR) was used to measure the survival
effects of neoadjuvant chemotherapy in NSCLC patients. The
individual HR of every trial was recorded directly if avail-
able. Otherwise, the individual HR for a specific trial was
calculated with the following formula:
ln(HR) O E/V
where O refers to observed number of deaths in the neoad-
juvant chemotherapy arm; E refers to log-rank expected
number of deaths in the neoadjuvant chemotherapy arm; and
V refers to variance of (O  E).
The values of (O  E) and V could be calculated from
the total number of deaths and the reported log-rank statistic
or its p value, as described by Parmar et al.19,20 The Kaplan-
Meier survival curve would be used for estimation of survival
data, if needed.
The calculation of individual HR and combined HR
were performed with the software of Review Manager (Com-
puter program, version 5.0; from The Nordic Cochrane Cen-
ter, Copenhagen, Denmark). When there was no significant
heterogeneity among included trials, the combined HR was
calculated by using a fix-effect model; otherwise, a random-
effect model would be used. A HR value of less than 1.0
would imply a survival advantage in the neoadjuvant chemo-
therapy arm. The value of HR would be considered as a
statistically significant result if its 95% confidence interval
(95% CI) did not overlap 1.0.
Heterogeneity across eligible trials was tested by two
ways: (1) 2 test, in which a p value of more than 0.1 would
indicate the absence of heterogeneity; and (2) I2 test, in which
I2  100%  (2  n  1)/2, and an I2 value of less than
50% would suggest a low possibility of heterogeneity.
RESULTS
A total of 247 new trials, designed as clinical trials
studying on the neoadjuvant chemotherapy in NSCLC, were
found out. However, only nine2,3,21–26 of them were RCTs or
phase III randomized trials and were identified as potential
eligible trials for this updated study. The other 238 trials were
ruled out. After a careful discussion, one trial, reported by
Pass et al.21 was excluded because postoperative radiation
therapy was added only in the surgery arm; another trial,
reported by Felip et al.,26 was also excluded because of an
absence of survival data. As a result, a total of six new trials
were identified to meet the criteria of inclusion for our study.
Finally, together with those 7 trials that had been
included in Burdett et al.’s meta-analysis, a total of 13 trials
were included into this study. Among them, six trials2–4,6,9,11
were reported from Europe, five10,22–25 from Asia, and two8,12
from North America. Nine eligible trials2–4,6,8–12 were pub-
lished in English and four22–25 in Chinese. All these 13
eligible trials were RCTs. The total number of randomized
patients in these trials was 3224, with 1637 in the neoadju-
vant chemotherapy arm and 1587 in the surgery-alone arm.
Platinum-based regimens of neoadjuvant chemotherapy were
used in all eligible trials. Characteristics of these eligible
trials are given in Table 1. Table 2 illustrates the method-
ological quality of 13 eligible RCTs.
It is of note that there were four Chinese trials22–25
included into this meta-analysis. Those four Chinese trials
were completed by different lung cancer centers of China,
and they were all RCTs, and most of them were large-scale
trials. Although the publication years of those trails were very
close to each other (2001–2004), the details of their study
designs, such as chemotherapy regimens and basic character-
istics of included patients, were not always the same. We also
noticed that the conclusions of those Chinese trails were not
consistent to each other, three of them supporting the addition
of neoadjuvant chemotherapy, but one not.
All eligible articles were reported in the form of full-
length articles, with exceptions of three trials (S9900, Sorensen
et al.’s, and CH.E.S.T.), which had been reported in the form of
abstracts in the ASCO meeting. There were totally 17 articles
(abstracts) serving as data sources of this study, because updated
articles (abstracts) were reported for 4 trials.3,5–8,12,27,28 We
extracted the information of the study design for a specific trial
from the primary article (abstract), which usually described the
study design in detail, whereas survival data were extracted from
the updated article (abstract) that was reported after a longer
follow-up time.
Overall Survival Analysis
Individual HRs of every eligible trial of neoadjuvant
chemotherapy, in terms of overall survival, were shown in
Figure 1. The individual HRs of nine trials3,6,8,9,11,22,24,25,28
were in favor of neoadjuvant chemotherapy plus surgery
(individual HR 1.0), whereas those of other four tri-
als2,4,10,23 were in favor of surgery alone (individual HR
1.0). Although the difference between the largest and the
smallest individual HRs was as large as 0.69 (95% CI,
1.19–0.50), significant heterogeneity between the 13 trials
was not found (p  0.20, I2  24%). Therefore, a fixed-
model effect was used in this analysis. Eventually, the com-
bined HR of these trials was 0.84 (95% CI, 0.77–0.92), which
was a statistically significant result (p  0.0001) and, as a
whole, was in favor of neoadjuvant chemotherapy.
Journal of Thoracic Oncology • Volume 5, Number 4, April 2010 Neoadjuvant Chemotherapy in NSCLC
Copyright © 2010 by the International Association for the Study of Lung Cancer 511




















Dautzenberg et al.4 Available No details NR NR 0.0 Log-rank test OS; DFS; MST NR









Zhou et al.22 Available Random number NR NR 4.17 Kaplan-Meier OS Yes
Depierre et al.9 Unavailable No details Central
telephone
Stage; N2 4.83 Kaplan-Meier;
log-rank test;
Cox model
OS; DFS; MST No
Liao et al.23 Available Envelope
randomization




Li et al.25 Available No details NR NR 11.7 Kaplan-Meier;
log-rank test
OS Yes





OS; DFS; MST NR
Yao et al.24 Available Random number NR NR NR Kaplan-Meier;
log-rank test
OS NR
Sorensen et al.11 Unavailable No details NR NR NR Kaplan-Meier;
log-rank test
OS; MST NR
S990012,28 Unavailable No details NR NR 5.37 Kaplan-Meier;
log-rank test
OS; DFS; MST NR




OS; DFS; MST NR
Ch.E.S.T.3,27 Unavailable No details NR NR NR Kaplan-Meier;
log-rank test
OS NR
NR, not recorded; OS, overall survival; DFS, disease-free survival; MST, median survival time; N2, ipsilateral mediastinal lymph node involvement; RCT, randomized
control trails.
TABLE 1. General Characteristics of 13 Eligible Trials
References Recruitment Stage
No.
Patients Histological Types Chemotherapy Regimen p
Dautzenberg et al.4 1985–1987 I–III 26 Sq: 21; ad: 4; large: 1 VCP  2 0.85
Roth et al.7,8 1987–1993 IIIa 60 Sq: 22; ad: 30; large: 6; others: 2 CEP  3 0.056
Rosell et al.5,6 1989–1991 IIIa 60 Sq: 42; ad: 14; large: 4 MIP  3 0.005
Zhou et al.22 1990–2001 III 624 Sq: 321; ad: 207; others: 96 BAI (21)/MVP (68)/CAP (36)/EP
(67)/VIP (30)/GP (30)/NP (32)/TP
(10)/TN (30)  2
0.01
Depierre et al.9 1991–1997 I–III 355 Sq: 263; ad: 60; large: 32 MIP  2 0.15
Liao et al.23 1995–1997 I–IIIa 211 Unavailable MVP/MAP  2 0.53
Li et al.25 1990–1995 III 137 Sq: 110; ad: 21; others: 6 CAP/EP  1 0.05
JCOG10 1993–1998 IIIa 62 Sq: 15; ad: 41; others: 6 VP  3 0.074
Yao et al.24 1990–2002 III 456 Sq: 252; ad: 169; others: 35 GP (47)/NP (35)/MVP (86)/EP (66)  2 0.01
Sorensen et al.11 1998–2004 Ib–IIIa 90 Unavailable TP  3 0.715
S990012,28 1999–2004 Ib–IIIa 336 Sq: 127; ad: 107; others: 102 TP  3 0.19
MRC LU222 1997–2005 I–III 519 Sq: 256; ad: 138; others: 125 MVP (70)/MIP (41)/NP (216)/PC (2)/
DC (69)/GP (130)  3
0.86
Ch.E.S.T.3,27 2000–2004 Ib–IIIa 270 Sq: 111; ad: 85; others: 74 GP  3 0.005
BAI, bronchial artery infusion; CAP, cyclophosphamide  adriamycin  cisplatin; CEP, etoposide  cyclophosphamide  cisplatin; DC, docetaxel  carboplatin; EP,
etoposide  cisplatin; GP, gemcitabine  cisplatin; MAP, mitomycin  adriamycin  cisplatin; MIP, mitomycin  ifosfamide  cisplatin; MVP, mitomycin  vindesine 
cisplatin; NP, navelbine cisplatin; TP, taxol carboplatin; TN, paclitaxel navelbine; VCP, vindesine cyclophosphamide cisplatin; VIP, vindesine ifosfamide cisplatin;
VP, vindesine  cisplatin; sq, squamous carcinoma; ad, adenocarcinoma; large, large cell carcinoma; p, p value on survival comparison.
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Sensitivity Analysis
It was obvious that the weights of two trials (Zhou et
al.22 and Yao et al.24) were the largest, and the individual HRs
of them were similar to the combined HR (Figure 1). To
ensure that the combined HR was not severely driven by the
two trials, we conducted a sensitivity analysis by taking them
out. After the removal, the combined HR for the remaining 11
trials, in terms of overall survival, was 0.83 (95% CI, 0.75–
0.93), which was in favor of neoadjuvant chemotherapy
significantly too (p  0.001).
To our knowledge, the four Chinese22–25 trials were in-
cluded into the meta-analysis for the first time. To test whether
the combined result was swayed by them or not, another sensi-
tivity analysis was preformed by taking all Chinese trials out of
the meta-analysis. Finally, a combined HR of 0.83 (95% CI,
0.73–0.93) with nine English trials was obtained, and it also
indicated a significant survival benefit of neoadjuvant chemo-
therapy in those NSCLC patients (p  0.002).
Subgroup Analysis
Stage III NSCLC patients were included in all the 13
trials. However, survival data of those patients were pre-
sented in only 8 trials,6,8–10,22–25 with 1586 eligible patients.
With the purpose of understanding the possible survival
benefits of neoadjuvant chemotherapy in stage III NSCLC
patients, a subgroup meta-analysis was performed. With
those eight trials, a subgroup combined HR of neoadjuvant
chemotherapy in stage III NSCLC patients was obtained as
0.84 (95% CI, 0.75–0.95; Figure 2), which illustrated that
neoadjuvant chemotherapy benefited stage III NSCLC pa-
tients significantly (p  0.005). Because survival data of
patients with stages I to II NSCLC were available in only one
trial (reported by Liao et al.23), we could not conduct a
subgroup analysis for those patients. However, according to
Liao et al.’s trial, it seemed that neoadjuvant chemotherapy
would not benefit those patient with stage I disease (HR 
0.99, 95% CI, 0.56–1.76, p  0.97) and may even be
FIGURE 1. HR plot for overall survival. The combined HR was obtained using a fixed-effect model. By definition, a HR 1
implies a survival advantage for neoadjuvant chemotherapy in operable NSCLC. Combined HR  0.84 (95% CI, 0.77–0.92;
p  0.0001). NSCLC, non-small cell lung cancer; NC, neoadjuvant chemotherapy arm; SUR, surgery alone arm; HR, hazard
ratio; CI, confidence interval.
FIGURE 2. HR plot for overall survival in only stage III NSCLC. The combined HR was obtained using a fixed-effect model. By
definition, a HR 1 implies a survival advantage for neoadjuvant chemotherapy in operable stage III NSCLC. Combined HR 
0.84 (95% CI, 0.75–0.95; p  0.005). NSCLC, non-small cell lung cancer; NC, neoadjuvant chemotherapy arm; SUR, surgery
alone arm; HR, hazard ratio; CI, confidence interval.
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detrimental in those with stage II disease (HR  2.35, 95%
CI, 1.03–5.38, p  0.042). Note that the numbers of eligible
patients with stage I disease and those with stage II disease
were 99 and 47, respectively.
Publication Bias Test
The possible publication bias among these 13 eligible
trials was tested by funnel plot. As shown in Figure 3, the
funnel plot was symmetrical, indicating that no obvious
publication bias occurred.
DISCUSSION
Although there have been arguments on neoadjuvant
chemotherapy for a long time, our study supported neoadju-
vant chemotherapy to be beneficial for operable NSCLC
patients in terms of overall survival. Theoretically, effective
neoadjuvant chemotherapy would facilitate operation by
shrinking the primary tumors and reducing possibly involved
lymph nodes and, thus, improve resectability.29–31 Neoadju-
vant chemotherapy may also reduce or eradicate so-called
“residual tumor cells”32–34and “micrometastatic lesions,”35–37
which are now considered to be related to postoperative
recurrence and metastases.
In this analysis, a combined HR value of 0.84 was
obtained according to overall survival, indicating that overall
survival of operable NSCLC patients in the neoadjuvant
chemotherapy arm was improved. This was a significant
result (95% CI, 0.77–0.92) and suggested a nearly 16%
reduction of death risk in the neoadjuvant arm, comparing
with the surgery-alone arm. It was similar to that of Burdett
et al.’s1 meta-analysis, in which a combined HR of 0.82 (95%
CI, 0.69–0.97) was obtained. Because bias test and sensitiv-
ity analysis showed no obvious publication bias or imbalance
among these eligible trials, we believe that this result was
reliable.
When only patients with stage III NSCLC were consid-
ered, the combined HR of neoadjuvant chemotherapy in terms
of overall survival was 0.84 (95% CI, 0.75–0.95), which was
nearly the same to the combined HR for all operable NSCLC
patients (stages I–III), indicating that no more or less survival
benefits occur in stage III NSCLC patients. This result was
TABLE 3. Trials Included in Different Meta-Analyses
Bergman et al.13 Nakamura et al.15 Burdett et al.1 This Study
Dautzenberg et al., 1990 Dautzenberg et al., 1990 Dautzenberg et al., 1990
Pass et al., 1992 Pass et al., 1992
Roth et al., 1998 Roth et al., 1998 Roth et al., 1998 Roth et al., 1998
Rosell et al., 1999 Rosell et al., 1999 Rosell et al., 1999 Rosell et al., 1999
Depierre et al., 2002 Depierre et al., 2002 Depierre et al., 2002 Depierre et al., 2002
JCOG, 2003 JCOG, 2003 JCOG, 2003 JCOG, 2003
S9900, 2006 S9900, 2007
Sorensen et al., 2005 Sorensen et al., 2005
MRC LU22, 2007
Zhou et al., 2001
Liao et al., 2003
Li et al., 2003
Yao et al., 2004
Ch.E.S.T., 2008
FIGURE 3. Funnel plot for publication bias test.
The funnel plot is symmetrical and indicates no
obvious publication bias.
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similar to the results reported by Berghmans et al.13 and
Nakamura et al.,15 even though the latter two studies both
failed to get any statistically significant result because of too
small number of eligible patients (n  331 in Nakamura et al.’s
and n  337 in Berghmans et al.’s study).
As for the role of neoadjuvant chemotherapy in those
patients with stage I and II disease, we think it is too early to
draw any conclusion, because corresponding data were yet
not sufficient by now. This meta-analysis was an updated
study of Burdett et al.’s meta-analysis,1 with the same pur-
pose of assessing the effectiveness of neoadjuvant chemo-
therapy in NSCLC patients. In Burdett et al.’s study, eligible
trials were searched in November 2004 and August 2005 by
searching MEDLINE (1966–2005), the Cochrane Library,
large international meeting of oncology, and reference lists of
relevant publications and book chapters. The methodological
aspect of each trial was assessed by the CONSORT state-
ment. Their meta-analysis included only seven RCTs, all of
which were published or reported in English. In this study, we
adopted the similar search methodology and inclusion criteria
of eligible trials as Burdett et al.’s meta-analysis. We updated
their study by extending the searching years (up to April
2009) and language (both English and Chinese), adding six
eligible trials, and using new ways of data extraction and
statistical management.
In this study, nearly half of these 13 eligible trials were
large-scale ones,2,3,9,22–24,28 among which more than 100
eligible patients were enrolled in each study arm. Comparing
to Burdett et al.’s and other previously published meta-
analyses1,13,15 concerning neoadjuvant in NSCLC, the num-
ber of eligible trials in this study was the most, as presented
in Table 3.
However, this meta-analysis is still far from perfect.
First, it is not an individual patient data analysis, and there-
fore, it precludes a more comprehensive analysis such as
adjusting for baseline factors and other differences that exist
between the trials from which the data were pooled. Further-
more, we could not discover the possible survival benefits of
neoadjuvant chemotherapy in different NSCLC patient
groups with different histologic types, detailed stages, ages,
general conditions, etc., of patients, because of inadequate-
ness of corresponding data in these eligible trials. Among
these 13 eligible trials of this study, there was none that was
designed to choose regimens of neoadjuvant chemotherapy
individually for every eligible patient according to their
personal characteristics, in view of individual treatment.38–42
Although all these eligible trials used platinum-based neoad-
juvant chemotherapy, the exact regimens among these trials
were multitudinous. Our study could not answer that which
regimens would be the best choice. Conversely, it might be a
design defect in some trials when some stage III NSCLC
patients were randomized into the surgery-alone arm, because
the standard of care for patients with stage III lung cancer,
independent of surgery, is to treat them with chemotherapy
with or without radiation therapy. Therefore, future studies
should avoid this. Also, our study could not answer whether
neoadjuvant chemotherapy is more beneficial than postoper-
ative adjuvant chemotherapy,43 which has been taken as a
standard treatment for most of operable patients.44,45
In summary, this is an updated meta-analysis of 13
eligible RCTs on neoadjuvant chemotherapy in operable
NSCLC patients. According to its result, neoadjuvant chemo-
therapy is a beneficial addition of surgery for operable
NSCLC patients, in terms of overall survival, comparing with
surgery alone. When only stage III NSCLC patients were
concerned, the result is similar. Because of data insufficien-
cies, the role of neoadjuvant chemotherapy in stage I and II is
inconclusive yet. At the same time, further studies are ex-
pected to locating neoadjuvant chemotherapy in a proper role
in the treatment strategy of NSCLC as a whole.
REFERENCES
1. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-
analysis of the literature: chemotherapy and surgery versus surgery alone
in non-small cell lung cancer. J Thorac Oncol 2006;1:611–621.
2. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in
patients with resectable non-small cell lung cancer: results of the MRC
LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up-
date of systematic review. Lancet 2007;369:1929–1937.
3. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. A phase III random-
ized study of surgery alone or surgery plus preoperative gemcitabine-
cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up
data of Ch.E.S.T. J Clin Oncol 2008;26:LAB7508.
4. Dautzenberg B, Benichou J, Allard P, et al. Failure of the perioperative
PCV neoadjuvant polychemotherapy in resectable bronchogenic non-
small cell carcinoma. Results from a randomized phase II trial. Cancer
1990;65:2435–2441.
5. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial com-
paring preoperative chemotherapy plus surgery with surgery alone in
patients with non-small-cell lung cancer. N Engl J Med 1994;330:153–
158.
6. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy
in stage IIIA non-small-cell lung cancer: a 7-year assessment of a
randomized controlled trial. Lung Cancer 1999;26:7–14.
7. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing
perioperative chemotherapy and surgery with surgery alone in resectable
stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673–
680.
8. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients
enrolled in a randomized trial comparing perioperative chemotherapy
and surgery with surgery alone in resectable stage IIIA non-small-cell
lung cancer. Lung Cancer 1998;21:1–6.
9. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemother-
apy followed by surgery compared with primary surgery in resectable
stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin
Oncol 2002;20:247–253.
10. Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing
induction chemotherapy followed by surgery with surgery alone for
patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
J Thorac Cardiovasc Surg 2003;125:254–260.
11. Sorensen HR, Ravn J, Hansen O, et al. Scandinavian phase III trial of
neoadjuvant chemotherapy in NSCLC stages IB-IIIA/T3. J Clin Oncol
2005;23:LAB7146.
12. Pisters K, Vallieres E, Bunn P, et al. A phase III trial of surgery alone
or surgery plus pre-operative (pre-op) paclitaxel/carboplatin (PC) che-
motherapy in early stage non-small cell lung cancer (NSCLC): Prelim-
inary results. Proc Am Soc Clin Oncol 2006;24:LBA7012 (Abstract).
13. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in
resectable non-small cell lung cancer with (neo)adjuvant chemotherapy:
results of a meta-analysis of the literature. Lung Cancer 2005;49:13–23.
14. Felip E, Rosell R. Neoadjuvant chemotherapy in non-small cell lung
cancer. Curr Med Chem 2002;9:893–898.
15. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Role of preoper-
ative chemotherapy for non-small-cell lung cancer: a meta-analysis.
Lung Cancer 2006;54:325–329.
Journal of Thoracic Oncology • Volume 5, Number 4, April 2010 Neoadjuvant Chemotherapy in NSCLC
Copyright © 2010 by the International Association for the Study of Lung Cancer 515
16. Brahmer JR, Ettinger DS. Non-small cell lung cancer: adjuvant and
neo-adjuvant chemotherapy. Respirology 2007;12:320–325.
17. Santo A, Genestreti G, Sava T, et al. Neo-adjuvant chemotherapy in
non-small cell lung cancer (NSCLC). Ann Oncol 2006;17:55–61.
18. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of
randomized controlled trials. The CONSORT statement. JAMA 1996;
276:637–639.
19. Parmar M, and Machi D. Survival Analysis: Practical Approach. Chich-
ester: Wiley; 1995.
20. Parmar MK, Torri V, Stewart L. Extracting summary statistics to
perform meta-analyses of the published literature for survival endpoints.
Stat Med 1998;17:2815–2834.
21. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Random-
ized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann
Thorac Surg 1992;53:992–998.
22. Zhou QH, Liu XL, Li L, et al. A randomized clinical trial of preoperative
neoadjuvant chemotherapy followed by surgery in the treatment of stage
III non-small cell lung cancer. Chin J Lung Cancer 2001;4:251–256.
23. Liao ML, Zhou YZ, Ding JA, et al. The study of peri-operative
chemotherapy in stage I-IIIa NSCLC. Zhonghua Yi Xue Za Zhi 2003;
83:962–966.
24. Yao K, Xiang MZ, Min JX, et al. A randomized clinical trial of
preoperative neoadjuvant chemotherapy in the treatment of stage III
non-small cell lung cancer. J Clin Oncol China 2004;31:611–613.
25. Li Q, Song YH, Zheng ZY, et al. Clinical evaluation of preoperative
short course chemotherapy in treatment of stage III non-small cell lung
cancer. Chin J Cancer Prev Treat 2005;10:505–507.
26. Felip E, Rosell R, Massuti B, et al. The NATCH trial: observations on
the neoadjuvant arm. Proc Am Soc Clin Oncol 2007;25:LBA 7578
(Abstract).
27. Scagliotti GV; on behalf of Ch.E.S.T. Investigators. Preliminary results
of Ch.E.S.T.: a phase III study of surgery alone or surgery plus
pre-operative gemcitabine-cisplatin in clinical early stages non-small
cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2006;23:LBA7023
(Abstract).
28. Pisters K, Vallieres E, Bunn P, et al; Southwest Oncology Group. S9900:
Surgery alone or surgery plus induction (ing) paclitaxel/carboplatin (PC)
chemotherapy in early stage non-small cell lung cancer (NSCLC):
follow-up on a phase III trial. J Clin Oncol 2007;25:LAB7520.
29. De Marinis F, Gebbia V, De Petris L. Neoadjuvant chemotherapy for
stage IIIA-N2 non-small cell lung cancer. Ann Oncol 2005;16:116–122.
30. Pujol JL, Le Chevalier T, Ray P, et al. Neoadjuvant chemotherapy of
locally advanced non-small cell lung cancer. Lung Cancer 1995;12:
107–18.
31. Milroy R, Macbeth F. Neoadjuvant chemotherapy in stage IIIa non-
small cell lung cancer. Thorax 1995;50:S25–S30.
32. Hosch SB, Scheunemann P, Izbicki JR. Minimal residual disease in
non-small-cell lung cancer. Semin Surg Oncol 2001;20:278–281.
33. Lequaglie C, Conti B, Brega M, Giudice G. Unsuspected residual
disease at the resection margin after surgery for lung cancer: fate of
patients after long-term follow-up. Eur J Cardiothorac Surg 2003;23:
229–232.
34. Sawabata N, Keller SM, Matsumura A, et al. The impact of residual
multi-level N2 disease after induction therapy for non-small cell lung
cancer. Lung Cancer 2003;42:69–77.
35. Gu CD, Osaki T, Oyama T, et al. Detection of micrometastatic tumor
cells in pN0 lymph nodes of patients with completely resected nonsmall
cell lung cancer: impact on recurrence and survival. Ann Surg 2002;235:
133–139.
36. Castaldo G, Tomaiuolo R, Sanduzzi A, Ponticiello A, Marchetiello I,
Salvatore F. Carcinoembryonic antigen mRNA analysis detects micro-
metastatic cells in blood from lung cancer patients. Eur Respir J
2003;22:418–421.
37. Huang JS, Dong QG, Bao GL, Han BH. Implication of micrometastatic
cancer cells in the peripheral blood on prognosis of non-small cell lung
cancer. Zhonghua Zhong Liu Za Zhi 2004;26:294–296.
38. Shigematsu H, Toyooka S, Suzuki M. The need for an individual
approach to lung cancer treatment. PLoS Med 2006;3:e206.
39. Yuan P, Miao XP, Zhang XM, et al. XRCC1 and XPD genetic poly-
morphisms predict clinical responses to platinum-based chemotherapy in
advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi
2006;28:196–199.
40. Smith S, Su D, Rigault L, Schwartz, P, et al. ERCC1 genotype and
phenotype in epithelial ovarian cancer identify patients likely to benefit
from paclitaxel treatment in addition to platinum-based therapy. J Clin
Oncol 2007;25:5172–5179.
41. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1
(ERCC1) in platinum-based treatment of non-small cell lung cancer with
special emphasis on carboplatin: a review of current literature. Lung
Cancer 2009;64:131–139.
42. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular
analysis-directed individualized therapy in advanced non-small-cell lung
cancer. J Clin Oncol 2007;25:2741–2746.
43. Strauss GM. Adjuvant vs neoadjuvant chemotherapy in resectable
NSCLC: is that the real question? Oncology 2009;23:534–538.
44. Betticher DC. Adjuvant and neoadjuvant chemotherapy in NSCLC: a
paradigm shift. Lung Cancer 2005;50:9–16.
45. National Comprehensive Cancer Network. NCCN Clinical Practice
Guidelines in Oncology: Non-small cell lung cancer (v. 2.2009). Avail-
able at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
Accessed February 5, 2009.
Song et al. Journal of Thoracic Oncology • Volume 5, Number 4, April 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer516
